Log in

Relevant bibliographies by topics / Remogliflozin / Journal articles

To see the other types of publications on this topic, follow the link: Remogliflozin.

Journal articles on the topic 'Remogliflozin'

Author: Grafiati

Published: 5 June 2025

Last updated: 2 August 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Remogliflozin.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shinde, Sagar, Shweta Avhad, Vidya Morkar, Chaitanya Patki, Hemant Chikhale, and Laxmikant Borse. "Overview on remogliflozin SGLT-2 inhibitor in the management of type-2 diabetic mellitus in human beings." Bulletin of the Karaganda University. “Biology, medicine, geography Series” 112, no. 4 (2023): 156–67. http://dx.doi.org/10.31489/2023bmg4/156-167.

Full text

Abstract:

Sodium-glucose transport protein 2 inhibitors have become a significant category of oral medications in order to manage type 2 diabetic mellitus, particularly in people with heart disease or kidney disease, and have been highly advised overall current studies advice on how to treat. They can reduce blood pressure and help people lose weight, but they also come with drawbacks like genitourinary infections. The newly approved remogliflozin combinations are the product study of the pharmaceutical business for a new pharmaceutical class and novel drug combination with a view to managing diabetes.

APA, Harvard, Vancouver, ISO, and other styles

2

Gupta, Vishal Kumar, Deepak Pannu, Mahendra Pal Singh, and Lalit Kumar. "Effect of SGLT-2 inhibitor (remogliflozin) plus DPP4 inhibitor (vildagliptin) on diabetic nephropathy in patients with type 2 diabetes mellitus comparison with combination of metformin and sulphonylureas." International Journal of Advances in Medicine 10, no. 6 (2023): 446–51. http://dx.doi.org/10.18203/2349-3933.ijam20231450.

Full text

Abstract:

Background: Diabetes is leading cause of renal failure in entire world. Approximately 20-40 percent of patients with diabetes develop diabetic nephropathy. Newer drugs like SGLT-2 inhibitors and DPP-4 inhibitors are valuable option for Diabetic Nephropathy. Remogliflozin etabonate (RE) is the latest addition to the SGLT2 inhibitor class of drugs that have been recently approved in India for the management of T2DM.This study was conducted to elaborate effect of SGLT2 inhibitor (remogliflozin) plus DPP4 inhibitor (vildagliptin) on diabetic nephropathy in patients of Type 2 DM. Methods: This hosp

APA, Harvard, Vancouver, ISO, and other styles

3

Moumita, Hazra. "A Clinical Pharmacological Study on the Prevailing Prescription Patterns Appraisal of the Combination Therapies of Metformin and Remogliflozin, Metformin and Sitagliptin, and Metformin and Gemigliptin, among Early Grade Type II Diabetic Patients." International Journal of Toxicological and Pharmacological Research 12, no. 11 (2022): 31–38. https://doi.org/10.5281/zenodo.11421036.

Full text

Abstract:

<strong>Background: </strong>Oral hypoglycemic response is brought about through the activation of 5’ adenosine monophosphate induced protein kinase by metformin, inhibition of dipeptidyl peptidase-4 by the dipeptidyl peptidase-4 inhibitors, sitagliptin and gemigliptin, and the inhibition of a selective insulin-independent sodium glucose cotransporter subtype 2 by remogliflozin. <strong>Objectives: </strong>The objective of this clinical pharmacological study is the prevailing prescription patterns appraisal of the combination therapies of metformin and remogliflozin, metf

APA, Harvard, Vancouver, ISO, and other styles

4

Sreelatha, Gangu, Ramgondola V. Laxmi, Manne Nikshitha, and Orugala Amulya. "RP-HPLC Method Development and Validation for the Estimation of Antidiabetic Drugs Remogliflozin Etabonate and Vildagliptin in Bulk and Pharmaceutical Dosage Form." INTERNATIONAL JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH (IJPER) 6, no. 01 (2024): 1–7. http://dx.doi.org/10.37021/ijper.v6i1.01.

Full text

Abstract:

Introduction: The present study was done to develop a rapidand precise method by using reverse-phase high-performance liquid chromatography.Materials and Methods: This method was developed for the validation of Remogliflozin etabonate and vildagliptin in pharmaceutical dosage forms. Chromatography was carried out on a hypersil C18 (4.6×150 mm, 5 μm) column using a mixture of acetonitrile: Water (50:50% v/v) as mobile phase at a flow rate of 1.0 mL/min. The detection was carried out at 259 nm.Results: The retention times of remogliflozin etabonate and vildagliptin were found to be 2.344 and 3.2

APA, Harvard, Vancouver, ISO, and other styles

5

CS, Kagarana, Patel KN, and Patel AB. "Forced Degradation Method Development and Validation for Simultaneous Determination of Vildagliptin, Metformin Hydrochloride and Remogliflozin Etabonate in Bulk and its Formulation by RP-HPLC." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 15, no. 01 (2024): 119–23. http://dx.doi.org/10.25258/ijpqa.15.1.19.

Full text

Abstract:

A simple and efficient stability-indicating method has been developed and validated for the simultaneous estimation of vildagliptin, metformin hydrochloride and remogliflozin etabonate in bulk and was applied on marketed formulations. KH2PO4 buffer (10 mM): Acetonitrile (70:30% v/v) at pH 5 was used as a mobile phase. Detection of drug peaks was at 215 nm by UV detector. The method was found to be linear in the concentration range of 2.5 to 7.5, 25 to 75 and 5 to 15 μg/mL for vildagliptin, metformin hydrochloride and remogliflozin etabonate, respectively. The limit of detection (LoD) and quant

APA, Harvard, Vancouver, ISO, and other styles

6

Markham, Anthony. "Remogliflozin Etabonate: First Global Approval." Drugs 79, no. 10 (2019): 1157–61. http://dx.doi.org/10.1007/s40265-019-01150-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Sengupta, Soumya, Sunita Sengupta, and Sagar Katare. "A real-world clinical experience on the effectiveness of remogliflozin etabonate in management of Indian patients with type II diabetes mellitus." International Journal of Research in Medical Sciences 9, no. 6 (2021): 1722. http://dx.doi.org/10.18203/2320-6012.ijrms20212242.

Full text

Abstract:

Background: The aim of the study was to evaluate effectiveness and safety of remogliflozin etabonate in a real-world outpatient setting in type 2 diabetes mellitus (T2DM) patients in India.Methods: A retrospective, observational, single-center study wherein medical records of adult patients (≥18 years old) with T2DM managed with remogliflozin 100 mg for at least three months at the diabetes care center in Jharkhand were retrieved. The effectiveness was assessed in terms of change from baseline in glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), tota

APA, Harvard, Vancouver, ISO, and other styles

8

Attimarad, Mahesh, Katharigatta Narayanaswamy Venugopala, Anroop Balachandran Nair, Nagaraja Sreeharsha, and Pran Kishore Deb. "Experimental Design Approach for Quantitative Expressions of Simultaneous Quantification of Two Binary Formulations Containing Remogliflozin and Gliptins by RP-HPLC." Separations 9, no. 2 (2022): 23. http://dx.doi.org/10.3390/separations9020023.

Full text

Abstract:

The aim of this study was to develop a fast RP-HPLC method for simultaneous measurement of two antidiabetic formulations (vildagliptin + remogliflozin and teneligliptin + remogliflozin) under identical experimental conditions. Using the Box–Behnken approach and response surface design, the interaction and quadratic influence of three variable parameters, acetonitrile %, pH of the mobile phase, and flow rate, on resolution between the peaks were optimized. To forecast the resolution of peaks (2.7 and 6.5) for the three anti-diabetic medications, the design space with desirability function was u

APA, Harvard, Vancouver, ISO, and other styles

9

Nimmagadda, Rajya L., and Sowjanya Gummadi. "Concurrent Estimation of a Three Combination Type-2 Anti-diabetic Oral Dosage Form by Ultra-performance Liquid Chromatography." INTERNATIONAL JOURNAL OF PHARMACEUTICAL QUALITY ASSURANCE 14, no. 04 (2023): 1171–77. http://dx.doi.org/10.25258/ijpqa.14.4.53.

Full text

Abstract:

Estimation of a three-combination dosage form containing metformin (MET), vildagliptin (VLDG), and remogliflozin etabonate (REMET) was performed by developing an economically simple and isocratic simultaneous method using ultra-performance liquid chromatograph (Alliance 1100 series) comprising of X-Bridge (50 × 4.6 mm, 2.5 μ) C18 column and photo diode array detector. 0.1 % v/v trifluoro acetic acid: acetonitrile (60:40% v/v) movable phase at 0.5 mL/min was used. The analytes were detected at a wavelength of 240.0 nm at 8.0 min. run time. The respective retention times of 1.004, 2.005, 5.118 m

APA, Harvard, Vancouver, ISO, and other styles

10

Sai, Prudhvi N. "NOVEL STABILITY INDICATING LC-MS/MS METHOD FOR THE SIMULTANEOUS ESTIMATION OF REMOGLIFLOZIN ETABONATE AND VILDAGLIPTIN HUMAN PLASMA." Journal of Medical pharmaceutical and allied sciences 10, no. 5 (2021): 3718–25. http://dx.doi.org/10.22270/jmpas.v10i5.1655.

Full text

Abstract:

The present study intended to develop an easy and novel Liquid Chromatography–Mass Spectrometry/Mass spectrometry (LC–MS/MS) method for simultaneous assay of remogliflozin etabonate and vildagliptin, a combined formulation used in treatment of type II diabetes in human plasma. Alogliptin drug was selected as internal standard and the analytes were isolated from the spiked plasma matrix using liquid-liquid extraction procedure and the extracts were chromatographed on Inertsil ODS (4.6 mm×100 mm, 5 μm) C18 column. The mobile phase comprises of methanol, acetonitrile and 0.1 % formic acid in 40:5

APA, Harvard, Vancouver, ISO, and other styles

11

Athul, H., P. Sai Lekshmi, and Elizabeth James. "Unveiling the itch: A compelling case report on remogliflozin-induced pruritus and rash." National Journal of Pharmacology and Therapeutics 3, no. 1 (2025): 78–80. https://doi.org/10.4103/njpt.njpt_47_24.

Full text

Abstract:

Abstract The therapy of type 2 diabetes has advanced significantly with the introduction of the sodium–glucose cotransporter 2 (SGLT2) inhibitor class of medications, which show benefits beyond glucose control, such as blood pressure reduction, weight loss, and protection of the kidneys and heart. The newest medication in the SGLT2 inhibitor class to be licensed in India for the treatment of type 2 diabetes is remogliflozin etabonate (RE). With the unusual characteristics of being taken as a prodrug, having active metabolites, and having a short half-life that requires a twice-daily dose, RE i

APA, Harvard, Vancouver, ISO, and other styles

12

Neelam, Ameera, and Anand Kanaki. "Efficacy and safety of remogliflozin etabonate in type 2 diabetes mellitus patients in a tertiary care hospital." International Journal of Basic & Clinical Pharmacology 10, no. 4 (2021): 353. http://dx.doi.org/10.18203/2319-2003.ijbcp20211014.

Full text

Abstract:

Background: Incidence and prevalence of diabetes have been steadily increasing with a raise of global prevalence about 8.5%. The major types of diabetes are differentiated by insulin deficiency versus insulin resistance. SGLT2 inhibitors are a new class of drugs that act by inhibiting glucose reabsorption in the proximal renal tubules. Remogliflozin a prodrug of remogliflozin, which is a potent and selective sodium-glucose co-transporter-2 inhibitor was used for the study. The objective of the study was to evaluate the efficacy and safety of Remogliflozin etabonate in reducing HbA1C and serum

APA, Harvard, Vancouver, ISO, and other styles

13

M. Tandrima and Kumar Shiva Gubbiyappa. "SIMULTANEOUS LC-MS/MS QUANTIFICATION METHOD FOR REMOGLIFLOZIN ETABONATE AND METFORMIN IN PLASMA SAMPLES: APPLICATION OF KINETIC STUDY IN RABBITS." RASAYAN Journal of Chemistry 16, no. 02 (2023): 779–86. http://dx.doi.org/10.31788/rjc.2023.1628240.

Full text

Abstract:

A new accurate LC–MS/MS methodology was needed for the simultaneous quantitation of remogliflozin etabonate and metformin in plasma samples. Chromatography was executed with BDS-Hyoersil, C18 (50mm×4.60mm, 5.0µ) reverse phasic analytical stationary system with movable solvent comprising of 0.10% HCOOH, methyl alcohol, and acetonitrile in the fraction of 10:45:45. Multiple reaction monitoring exhibits ionic conversions at m/e 130.14 →85.08, m/e 523.26 → 271.18 and 586.19 → 57.07 for Metformin (MTF), Remogliflozin etabonate (RME), Fosamprenavir internal standard (IS) correspondingly. Method reco

APA, Harvard, Vancouver, ISO, and other styles

14

O'Connor-Semmes, Robin L., Erik P. Sandefer, Elizabeth K. Hussey, et al. "Regional gastrointestinal delivery of remogliflozin etabonate in humans." Biopharmaceutics & Drug Disposition 34, no. 2 (2013): 79–86. http://dx.doi.org/10.1002/bdd.1824.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Bade, Shital, Vikram Veer, and Ashok Bhosale. "Analytical Method Development and Validation of RP-HPLC For Estimation of Remogliflozin Etabonate in Bulk and Pharmaceutical Dosage Form." Journal of Neonatal Surgery 14, no. 32S (2025): 4510–19. https://doi.org/10.63682/jns.v14i32s.8144.

Full text

Abstract:

A straightforward, creative, and selective reverse phase-high performance liquid chromatography (RP-HPLC) method that has been developed and optimized can be used to quantify remogliflozin etabonate (RMZ) in both bulk and dose forms. Phenomenex C18, 250 mm X 4.6 mm, 5 µm, was used as the stationary phase for the analysis at a flow rate of 1.2 mL/min, injection volume of 20 µl, run time of 8 min, and detection wavelength of 228 nm. The mobile phase was a mixture of 0.1% trifluoroacetic acid and methanol in a ratio of 30:70 v/v. Remogliflozin Etabonate Retention Time was evaluated by the analyti

APA, Harvard, Vancouver, ISO, and other styles

16

J. Panchal, B. Dhaduk, and J. Dhalani. "STABILITY INDICATING ISOCRATIC RP-HPLC AND SECOND DERIVATIVE UV SPECTROSCOPIC METHODS FOR SIMULTANEOUS DETERMINATION OF REMOGLIFLOZIN ETABONATE AND VILDAGLIPTIN HYDROCHLORIDE." RASAYAN Journal of Chemistry 16, no. 02 (2023): 579–87. http://dx.doi.org/10.31788/rjc.2023.1628212.

Full text

Abstract:

Remogliflozin and Vildagliptin are the latest drug combination in order to treat type 2 diabetes. The present work describes a comparative study of 2nd-ordered derivative UV and isocratic stability indicating RP-HPLC methods for simultaneous determination of Remogliflozin and Vildagliptin in the drug and its formulation. The HPLC method was established with a C18 column and the mobile phase with Buffer (pH-6.50): Acetonitrile: Methanol ratio of 55:44:1, at 1.2 ml/min flow and wavelength of 210 nm. The UV spectrophotometric method works on spectrophotometry with 2nd order derivative spectra(2D)

APA, Harvard, Vancouver, ISO, and other styles

17

Shimizu, Kazuo, Hideki Fujikura, Nobuhiko Fushimi, et al. "Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor." Bioorganic & Medicinal Chemistry 34 (March 2021): 116033. http://dx.doi.org/10.1016/j.bmc.2021.116033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Shah, Dimal, Ishita Gondalia, Vandana Patel, Ashok Mahajan, and Usmangani K. Chhalotiya. "Stability indicating liquid chromatographic method for the estimation of remogliflozin etabonate." Journal of Chemical Metrology 14, no. 2 (2020): 125–32. http://dx.doi.org/10.25135/jcm.46.20.07.1734.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Suryavanshi, Vallabh D., Sanjay Sharma, and Jagdish K. Sahu. "Review on Characteristics and Analytical Methods of Remogliflozin Etabonate: An Update." Mini-Reviews in Medicinal Chemistry 22, no. 9 (2022): 1341–50. http://dx.doi.org/10.2174/1389557521666211007115611.

Full text

Abstract:

Abstract: Hyperglycemia and its associated disorders like Diabetes mellitus are engulfing the world’s population at a faster pace. New-age medications like the SGLT 2 inhibitors have found their place in the run to combat DM. Drugs with these properties have proven to be effective in treating hyperglycemia, obesity, and major cardiac disorders. The interesting fact about these drugs is that they act independently of insulin levels in the patient’s body. The fact that they even bypass the side effects shown by currently used anti-diabetic medications has attracted the world’s hope to neutralize

APA, Harvard, Vancouver, ISO, and other styles

20

BHATTACHARYA, SUPRATIK, and SAGAR KATARE. "2217-PUB: Remogliflozin in Indian T2DM Patients: A Real-World Study." Diabetes 69, Supplement 1 (2020): 2217—PUB. http://dx.doi.org/10.2337/db20-2217-pub.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Mikhail, Nasser. "Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus." Expert Opinion on Investigational Drugs 24, no. 10 (2015): 1381–87. http://dx.doi.org/10.1517/13543784.2015.1061501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Aveek Datta, Dr. Subhasis Maity, Dr. Miltu Kr. Ghosh, and Dr. Kuntal Hazra. "Design, Characterisation and Evaluation of Sustained Release Formulation of Remogliflozin Etabonate." Asian Journal of Pharmaceutical Research and Development 12, no. 6 (2024): 18–24. https://doi.org/10.22270/ajprd.v12i6.1431.

Full text

Abstract:

Now-a-days Type 2 diabetes mellitus is a very crucial common disease and emerging condition that glucose level of Human body cannot be controlled. In case of Type-2 diabetes mellitus, pancreas does not produce enough insulin. In such a condition, we have to thing for a medicament for treating the disease; Remogliflozin Etabonate is such type of drug that efficacious and safe agent that we can administer in our body. The Half-Life of the drug is 120 minutes.This research has taken into consideration on improving the release pattern of the drug by sustaining its action at maximum level of time,

APA, Harvard, Vancouver, ISO, and other styles

23

G, Manohar, Gopi G, and Prakash Reddy P.K. "Formulation and Evaluation of Microparticle Controlled Release Solid Dosage form of Remogliflozin." Asian Journal of Medical and Pharmaceutical Sciences 12, no. 1 (2024): 41–48. http://dx.doi.org/10.30904/j.ajmps.2024.4693.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Nakano, Shigeru, Kenji Katsuno, Masayuki Isaji, et al. "Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male Mice." Journal of Clinical and Experimental Hepatology 5, no. 3 (2015): 190–98. http://dx.doi.org/10.1016/j.jceh.2015.02.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Dash, Ranjeet Prasad, R. Jayachandra Babu, and Nuggehally R. Srinivas. "Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview." Xenobiotica 47, no. 11 (2016): 1015–26. http://dx.doi.org/10.1080/00498254.2016.1247219.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Sanket, G. Kadam*1 Madhuri D. Game2 Vaibhav V. Narwade3. "Bioanalytical Method Development And Validation For The Simultaneous Estimation Of Remogliflozin Etabonate, Vildagliptin And Metformin In Tablet Dosage Form." International Journal in Pharmaceutical Sciences 2, no. 5 (2024): 1782–92. https://doi.org/10.5281/zenodo.11402256.

Full text

Abstract:

An HPLC method was developed and validated for the simultaneous estimation of Remogliflozin Etabonate, Vildagliptin, and Metformin in tablet dosage form. These drugs are commonly used in the treatment of type 2 diabetes mellitus. The method development involved optimization of chromatographic conditions, selection of suitable solvents and wavelengths, and preparation of standard solutions. The chromatographic conditions were established using a Younglin-HPLC system with a C18 analytical column and a mobile phase consisting of Buffer: Methanol (85:15). The method exhibited good accuracy, linear

APA, Harvard, Vancouver, ISO, and other styles

27

Mohan, Viswanathan, Ambrish Mithal, Shashank R. Joshi, SR Aravind, and Subhankar Chowdhury. "Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy." Drug Design, Development and Therapy Volume 14 (June 2020): 2487–501. http://dx.doi.org/10.2147/dddt.s221093.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Wilkison, W., B. Cheatham, and S. Walker. "O047 : Remogliflozin etabonate reduces insulin resistance and liver function enzymes: Role for treatment of nash." Journal of Hepatology 62 (April 2015): S211—S212. http://dx.doi.org/10.1016/s0168-8278(15)30055-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Chawla, Rajeev. "Abstract #806690: Real World Effectiveness and Tolerability of Remogliflozin in Uncontrolled Type 2 Diabetes Patients." Endocrine Practice 26 (May 2020): 134. http://dx.doi.org/10.1016/s1530-891x(20)39729-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

PANCHAL, J., and J. Dhalani. "Novel Ultra-Fast Liquid Chromatography Method for Simultaneous Quantification of Metformin Hydrochloride and Remogliflozin Etabonate." Asian Journal of Chemistry 35, no. 9 (2023): 2055–60. http://dx.doi.org/10.14233/ajchem.2023.27910.

Full text

Abstract:

An advanced formulation having remogliflozin etabonate (REM) and metformin hydrochloride (MET) for the treatment of diabetes was recently approved. However, there hasn't been any information reported on a UFLC technique for simultaneously quantifying both active substances. Therefore, aim of the study was the development of an ultra-fast isocratic liquid chromatography method for quantification of MET and REM in API and dosage form. The reversed phase-UFLC method was developed with a very short run time of only 3 min with no interference due to blank. The compounds were separated using Shimadz

APA, Harvard, Vancouver, ISO, and other styles

31

U. Shinde, Samadhan, Ruchita S. Bardiya, Pritam S. Jain, Atul A. Shikhedkar, and Akhil A. Nagar. "COMPARISON OF ACID DEGRADANT PRODUCT WITH METABOLIC PATHWAY OF REMOGLIFLOZIN ETABONATE IN DEVELOPED AND VALIDATED RP-HPTLC METHOD." Indian Drugs 59, no. 11 (2022): 46–53. http://dx.doi.org/10.53879/id.59.11.13183.

Full text

Abstract:

Forced degradation studies in tablet and bulk formulations of remogliflozin etabonate have been developed using a precise and sensitive high performance thin layer chromatographic method. The silica gel RP-18 F254S plates were used as the stationary phase and ACN: water: ammonia solution (8:2:0.5 V/V/V) was used as the mobile phase for estimation. The proposed method was successfully validated, showing the Rf of the drug as 0.72 at 229 nm. The method was observed to be linear in the range of 500-3000 ng band-1 and then degradation was estimated by forced degradation pathway. In the forced degr

APA, Harvard, Vancouver, ISO, and other styles

32

SHANKAR, ANAND. "1114-P: Comparison of Remogliflozin and Canagliflozin as Add-On Therapy in Indian Uncontrolled T2DM Subject." Diabetes 69, Supplement 1 (2020): 1114—P. http://dx.doi.org/10.2337/db20-1114-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Panchal, Jignesh, and Jayesh Dhalani. "An optimization through experimental design approach for simultaneous quantification of Remogliflozin and Teneligliptin by RP-UFLC." Research Journal of Chemistry and Environment 28, no. 11 (2024): 16–24. http://dx.doi.org/10.25303/2811rjce016024.

Full text

Abstract:

The combination of teneligliptin (TEN) with remogliflozin etabonate (REM) is the latest FDC approved for the treatment of type-2 diabetes. There is no QBD optimized UFLC method reported with short runtime for quantification of TEN and REM. Hence this research work aimed to find a new way to quantify a novel antidiabetic combination of TEN and REM using RP-UFLC technique with possible minimum run time, optimized with QBD. The method was executed using the Agilent Eclipse XDB C-18 column (150 x 4.6 mm; 5 μm), with the mobile phase comprising of buffer and acetonitrile (41:59) at a flow rate of 2

APA, Harvard, Vancouver, ISO, and other styles

34

Yadav, Ramji Lal, Rahul Dev, Ruchita Santra, and Priti Jain. "Stability Indicating Method for the Assay of Remogliflozin Etabonate and its Related Substances by RP-HPLC." Analytical Chemistry Letters 13, no. 1 (2023): 73–81. http://dx.doi.org/10.1080/22297928.2023.2176785.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Attimarad, Mahesh, Katharigatta N. Venugopala, Bandar E. Al-Dhubiab, Rafea Elamin Elgack Elgorashe, and Sheeba Shafi. "Development of Ecofriendly Derivative Spectrophotometric Methods for the Simultaneous Quantitative Analysis of Remogliflozin and Vildagliptin from Formulation." Molecules 26, no. 20 (2021): 6160. http://dx.doi.org/10.3390/molecules26206160.

Full text

Abstract:

Three rapid, accurate, and ecofriendly processed spectrophotometric methods were validated for the concurrent quantification of remogliflozin (RGE) and vildagliptin (VGN) from formulations using water as dilution solvent. The three methods developed were based on the calculation of the peak height of the first derivative absorption spectra at zero-crossing points, the peak amplitude difference at selected wavelengths of the peak and valley of the ratio spectra, and the peak height of the ratio first derivative spectra. All three methods were validated adapting the ICH regulations. Both the ana

APA, Harvard, Vancouver, ISO, and other styles

36

Sykes, A. P., G. L. Kemp, R. Dobbins, et al. "Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes." Diabetes, Obesity and Metabolism 17, no. 1 (2014): 98–101. http://dx.doi.org/10.1111/dom.12393.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

O’Connor-Semmes, Robin, Susan Walker, Anita Kapur, et al. "Pharmacokinetics and Pharmacodynamics of the SGLT2 Inhibitor Remogliflozin Etabonate in Subjects with Mild and Moderate Renal Impairment." Drug Metabolism and Disposition 43, no. 7 (2015): 1077–83. http://dx.doi.org/10.1124/dmd.114.062828.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Kotadiya, Rajendra, and Prachi Joshi. "Simultaneous estimation of remogliflozin etabonate and vildagliptin in a tablet formulation: UV spectrophotometric and HPLC-PDA method." Journal of Chemical Metrology, no. 2 (March 10, 2023): 1–10. http://dx.doi.org/10.25135/jcm.82.2301.2693.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

MOHAN, BRIJ, MANOJ S. CHAWLA, RAHUL R. KODGULE, et al. "800-P: Phase 3 Results of Fixed-Dose Combination of Remogliflozin Etabonate and Vildagliptin in Indian T2DM Patients." Diabetes 70, Supplement 1 (2021): 800—P. http://dx.doi.org/10.2337/db21-800-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Sykes, A. P., R. O'Connor-Semmes, R. Dobbins, et al. "Randomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes." Diabetes, Obesity and Metabolism 17, no. 1 (2014): 94–97. http://dx.doi.org/10.1111/dom.12391.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Waditake, Poonam Dada, Mahesh Hari Kolhe, Mayuri Kailas Mate, Rohit Jaysing Bhor, Pratibha Sudhakar Bhalerao, and Manjusha Pandharinath Mhaske. "Stability Indicating Bioanalytical Method Development and Validation for Estimation of Remogliflozin Etabonate by RP-HPLC in Human Plasma." International Journal of Pharmaceutical Investigation 14, no. 4 (2024): 1131–37. http://dx.doi.org/10.5530/ijpi.14.4.123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Sengupta, Shantanu, Jayagopal Pathiyil Balagopalan, ashwani mehta, et al. "EFFECT OF REMOGLIFLOZIN ON BIOMARKERS COMPARED TO EMPAGLIFLOZIN INPATIENTS OF TYPE 2 DIABETES MELLITUS WITH CHRONIC HEART FAILURE." Journal of the American College of Cardiology 81, no. 8 (2023): 316. http://dx.doi.org/10.1016/s0735-1097(23)00760-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Shailesh kumar, Patel Vishva, and Kapupara Pankaj Popatlal. "Stability Indicating RP-HPLC Method Development and Validation for the Simultaneous Quantification of Remogliflozin Etabonate and Metformin HCl." Indian Journal of Pharmaceutical Education and Research 59, no. 1s (2025): s274—s282. https://doi.org/10.5530/ijper.20253781.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Attimarad, Mahesh, Anroop Balachandran Nair, Sreeharsha Nagaraja, Bandar Essa Aldhubiab, Katharigatta Narayanaswamy Venugopala, and Shinu Pottathil. "Smart UV Derivative Spectrophotometric Methods for Simultaneous Determination of Metformin and Remogliflozin: Development, Validation and Application to the Formulation." Indian Journal of Pharmaceutical Education and Research 55, no. 1s (2021): s293—s302. http://dx.doi.org/10.5530/ijper.55.1s.62.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Mudaliar, S., D. A. Armstrong, A. A. Mavian, et al. "Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes." Diabetes Care 35, no. 11 (2012): 2198–200. http://dx.doi.org/10.2337/dc12-0508.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Katare, S. S., S. Suryawanshi, H. Barkate, R. Kodgule, and M. Tandon. "Effect of Remogliflozin Etabonate on Cardiovascular Risk Factors in Patients with Type-2 Diabetes Mellitus: Summary from Development Trials." Indian Heart Journal 71 (November 2019): S68. http://dx.doi.org/10.1016/j.ihj.2019.11.146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Gulhane, Chaitanya, and Madhuri Game. "Comparative Studies on Simultaneous Estimation of Metformin, Empagliflozin, Remogliflozin, Glimepride and Gliclazide by using RP-HPLC and Diol Technique." INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY 14, no. 01 (2024): 378–84. http://dx.doi.org/10.25258/ijddt.14.1.55.

Full text

Abstract:

Retaining extremely polar metformin and its combination with other non-polar antidiabetic drugs can be difficult and challenging by using the most common reverse-phase high-performance liquid chromatography (RP-HPLC). The retention time of metformin is comparatively short when separated, utilizing C18-based RPC. Peak fronting and tailing effects are commonly observed with metformin (MET), its combination with highly polar antidiabetic medicines, and early elution with void volume. However, normal phase chromatography may occasionally be rendered ineffective due to the low solubility of polar a

APA, Harvard, Vancouver, ISO, and other styles

48

Attimarad, Mahesh, Anroop B. Nair, Nagaraja Sreeharsha, Bandar E. Al-Dhubiab, Katharigatta N. Venugopala, and Pottathil Shinu. "Development and Validation of Green UV Derivative Spectrophotometric Methods for Simultaneous Determination Metformin and Remogliflozin from Formulation: Evaluation of Greenness." International Journal of Environmental Research and Public Health 18, no. 2 (2021): 448. http://dx.doi.org/10.3390/ijerph18020448.

Full text

Abstract:

The recent trend in green analytical chemistry is the development of green analytical methods using environmentally friendly solvents. Therefore, three ecofriendly manipulated UV spectroscopic techniques have been validated for the concurrent quantification of newly approved remogliflozin etabonate (REM) and metformin HCl (MET) tablets using water as a solvent. The first method was established using first derivative absorption spectroscopic method by determining the peak amplitude at 233.0 nm for REM and 252.2 nm for MET, a zero crossing of one the component. The second and third methods were

APA, Harvard, Vancouver, ISO, and other styles

49

Ahsan, Sajjad. "Abstract #1004069: Effectiveness of Remogliflozin and Vildagliptin Combination in Type 2 Diabetes Mellitus Patients Uncontrolled on Triple Oral Drug Therapy." Endocrine Practice 27, no. 6 (2021): S62. http://dx.doi.org/10.1016/j.eprac.2021.04.600.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

GUPTA, VISHAL K. "1139-P: Remogliflozin (SGLT2 Inhibitor) Significantly Reduces Albuminuria and Delays the Progression of Nephropathy in Type 2 Diabetes Mellitus Patients." Diabetes 69, Supplement 1 (2020): 1139—P. http://dx.doi.org/10.2337/db20-1139-p.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!